INICIO

Continuation of the Revista Mexicana de Cardiología

  • Home
  • Instructions for authors
    • Instructions for authors
    • Regulations for the publication of supplements
  • Publish
  • Directory
  • Publications
    • Current issue                  
    • All issues
  • About Us
    • About the Journal            
    • Publisher Policies
    • Previous Titles
    • Editorial Management
  • Contact





2026, Number 1

Cardiovasc Metab Sci 2026; 37 (1)

WHO 2025 HIV guideline: Integrating cardiometabolic care into HIV services

Abiola-Adepoju, Victor; Abdulrahim, Abdulrakib; Jamil, Safayet

ABSTRACT

The World Health Organization (WHO)’s 2025 human immunodeficiency virus (HIV) service delivery guideline recognizes that the epidemic is entering a new era marked by ageing, multimorbidity, and limited resources.1 Although global Antiretroviral Therapy (ART) coverage now reaches 31.6 million people, only 73% of People living with HIV (PLHIV) achieve viral suppression.2 Increasing life expectancy increases vulnerability to chronic comorbidities. In sub-Saharan Africa, 5-10% of PLHIV have diabetes, and 20-25% have hypertension. A meta-analysis of 10,916 participants across East Africa found hypertension prevalence at 19.75%, with alcohol use, diabetes, and longer HIV duration as key predictors.3 Traditional HIV clinics, structured for infectious disease management, remain poorly equipped for lifelong chronic care. Without addressing hypertension and diabetes, cardiovascular risk will escalate, ultimately threatening viral suppression and the hard-won gains of the HIV response.
  FULL TEXT PDF   FLIPBOOK

Keywords





  • Send manuscript
  • Instructions for authors
  • Recent
  • TOP 5
  • The triglyceride-glucose index and its usefulness in clinical practice as a...
    2026, Vol.37, Núm. 1
  • WHO 2025 HIV guideline: Integrating cardiometabolic care into HIV services
    2026, Vol.37, Núm. 1
  • Challenges in Mexico in the management of out-of-hospital cardiac arrest
    2026, Vol.37, Núm. 1
  • Traditional and/or clinical epidemiology. One pillar of modern medicine
    2026, Vol.37, Núm. 1
  • The 2026 Mexican Consensus on Arterial Hypertension: Expert Group on Arterial...
    2026, Vol.37, Núm. 1
  • Effectiveness and safety of amphepramone in a slow release as part of the...
    2007, Vol.18, Núm. 1
  • Etiology and pathophysiology of type 2 diabetes mellitus
    2011, Vol.22, Núm. 1
  • Long QT syndrome secondary to drug interaction between hydroxychloroquine and...
    2018, Vol.29, Núm. 2
  • Early repolarization. Normal or dangerous?
    2011, Vol.22, Núm. 3
  • Official Mexican Standard NOM-030-SSA2-2009. For the prevention, detection,...
    2011, Vol.22, Núm. 3


Cardiovascular and Metabolic Science Vol. 37, Num. 1, Enero-Marzo 2026. Es una publicación trimestral editada por la Asociación Nacional de Cardiólogos de México. Magdalena 135. Col. Del Valle. Del. Benito Juárez. Ciudad de México, México. C.P. 03103. Tel. 5556368002 http://www.medigraphic.com/cms ancam@ancam.org.mx https://www.medigraphic.com/cms/ E-mail: revmexcardiol@gmail.com Editor responsable. Dr. Eduardo Meaney Mendiolea. Reserva de Derechos al Uso Exclusivo Nº 04-2019-022717130200-102. ISSN impreso: 2683-2828, ISSN electrónico: 2954-3835. Otorgados por el Instituto Nacional del Derecho de Autor. Responsable de la última actualización de este número, Departamento de Internet, Graphimedic, S.A. de C.V., Ing. Luis Rosales Jiménez, Coquimbo 936, Col. Lindavista, Delegación Gustavo A. Madero, C.P. 07300, Ciudad de México, México. Fecha de última modificación, 1 de abril de 2026.

 

2026     |     https://www.cardiovascularandmetabolicscience.org.mx/